AURORA, Colorado, Sept. 13 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release:

* * *

Zidesamtinib Demonstrates 93% Response Rate in TKI-Naive Patients With Advanced ROS1-Positive NSCLC

*

(SEOUL, Republic of Korea -September 14th at 10:45 a.m. Korea Standard Time) -New results from the global Phase I/II ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patien . . .

Click here for more information about our products